Compare Repligen Corporation Common Stock (RGEN) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Taskus Inc — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Taskus Inc trades at $8.1 (market cap $750.00M). The key difference: Repligen Corporation Common Stock is far larger — about 14.9× Taskus Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Taskus Inc for 35 Days on average.
| RGEN | TASK | |
|---|---|---|
Market Cap | $11.14B | $750.00M |
Volume | 1,259,263 | 195,383 |
Sector | Health | Technology |
52-Week High | $194.57 | $14.30 |
52-Week Low | $102.87 | $4.57 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $11.02B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TaskUs (TASK) trades at $8.14, up 1.88% with bullish technical signals from moving averages. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Valuation metrics appear attractive with P/E of 7.05 and P/S of 0.62. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI services growth offsetting declines in other segments.
The outlook remains positive with analyst consensus price target of $9.33 representing 15% upside potential. Key opportunities include AI services expansion growing 26% annually, while risks involve margin compression from higher labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
